Nice to see the pop today.

Makes one wonder a bit if people might be buying as a result of the AZ aquisition of ZS. Interesting Pascal Soriot saying the acquisition "complements our strategic focus on cardiovascular and metabolic disease by adding a potential best-in-class treatment to our portfolio of innovative medicines." Sounds to me like something that might be said about RVX also, especially in light of the 208-Crestor connection.

RVX is definitely behind ZS in clinical terms but ZS faces direct competition upon approval. At the same time RVX would seem to offer more potential clinical opportunities. $2.7B USD for something that "could generate peak annual sales of more than $1B". Who knows what they might offer for something not as clinically advanced, perhaps facing less competition and offering a potentially much larger market opportunity, especially in the context of existing synergies.

Definitely just speculating but interesting none the less.